PDE11A Mutation Detection for Cushing Syndrome Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods and compounds to research, screen for, treat, or prevent Cushing's syndrome and its underlying causes, particularly the newly discovered form of micronodular bilateral adrenal hyperplasia (BAH) presenting in young children, as current knowledge is limited about this condition.
Innovation Solution
The method involves determining the activity or expression level of the PDE11A protein in mammals, comparing it to a negative control, and detecting mutations in the PDE11A gene, using specific nucleic acid sequences and vectors to identify and modulate the protein's activity, and evaluating the safety of inhibitors to develop effective treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current screening methods are used for Cushing's syndrome, then existing diagnostic capabilities are maintained, but the ability to detect the newly discovered form of micronodular BAH is insufficient
Solution Approach 1:
The patent changes the detection parameter from general hormonal assays to specific PDE11A gene mutation detection and PDE11A protein expression level measurement. This parameter change enables precise detection of the newly discovered micronodular BAH form while maintaining compatibility with existing diagnostic frameworks for Cushing's syndrome.
Solution Approach 2:
The patent creates a universal screening method that can detect multiple forms of Cushing's syndrome and BAH through a single PDE11A-based assay system. This multi-functional approach allows the same diagnostic tool to identify both classic and newly discovered disease forms, improving both precision and adaptability simultaneously.
2Measurement precision
If PDE11A activity determination is performed to screen for Cushing's syndrome, then diagnostic accuracy for the new disease form is improved, but the complexity of the screening method increases
Solution Approach 1:
The patent replaces complex multi-step diagnostic procedures with a simplified molecular biology approach based on PDE11A gene detection and protein expression analysis. This substitution uses well-established laboratory techniques (PCR, Western blotting, ELISA) to achieve high diagnostic accuracy without requiring complex equipment or procedures.
3Loss of time
If mutation detection in PDE11A is implemented, then early diagnosis of micronodular BAH is enabled, but the cost and time required for screening increases
Solution Approach 1:
The patent establishes PDE11A mutation detection as a preliminary screening step that can be performed early in the diagnostic workflow. By identifying patients with PDE11A mutations before proceeding to more complex confirmatory tests, the method enables early diagnosis while reducing overall screening costs and time for the general population.
Data Source
AI summary
The invention provides previously uncharacterized variants of PDE11A that are correlated with a newly discovered form of Cushing Syndrome that presents at a young age. The invention also provides methods useful to research, screen for, treat, or prevent diagnose the disease using the PDE11A variants, as well as other methods relating thereto.